Biomarker-guided application of low-dose anakinra in an acute respiratory distress syndrome patient with severe COVID-19 and cytokine release syndrome

Autor: S Wiebecke, S Frantz, D Weismann, H P Tony, Marc Schmalzing, M J Steinhardt, H Klinker
Rok vydání: 2020
Předmět:
Male
medicine.medical_specialty
Coronavirus disease 2019 (COVID-19)
viruses
Pneumonia
Viral
Immunology
macromolecular substances
Acute respiratory distress
Severity of Illness Index
Biomarkers
Pharmacological
Betacoronavirus
03 medical and health sciences
0302 clinical medicine
Rheumatology
Internal medicine
Severity of illness
medicine
Humans
Immunology and Allergy
030212 general & internal medicine
Respiratory system
Lactate Dehydrogenases
Pandemics
030203 arthritis & rheumatology
Anakinra
Dose-Response Relationship
Drug
Interleukin-6
SARS-CoV-2
business.industry
musculoskeletal
neural
and ocular physiology
COVID-19
virus diseases
General Medicine
Middle Aged
medicine.disease
Respiration
Artificial
Interleukin 1 Receptor Antagonist Protein
Cytokine release syndrome
Pneumonia
Treatment Outcome
nervous system
Antirheumatic Agents
Ferritins
Biomarker (medicine)
Drug Monitoring
Coronavirus Infections
Cytokine Release Syndrome
business
medicine.drug
Zdroj: Scandinavian Journal of Rheumatology
ISSN: 1502-7732
0300-9742
Popis: While the majority of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infections show a subacute development with mild to no symptoms, a severe course with acute respiratory distress s...
Databáze: OpenAIRE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje